[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"gastric-neoplasm\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:gastric-neoplasm":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,49,78,112,136,183,208],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":29,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100405330","surgery-in-gastrointestinal-stromal-tumors-gists-for-treatment-tumor-modeling-and-genomic-analysis-100405330",false,"NCT04557969","Surgery in Gastrointestinal Stromal Tumors (GISTs) for Treatment, Tumor Modeling, and Genomic Analysis","Prospective Study of Surgery in Gastrointestinal Stromal Tumors (GISTs) for Treatment, Tumor Modeling, and Genomic Analysis","* INCLUSION CRITERIA:\n* Histological confirmation or clinical presentation suspicious of GIST; histological confirmation will be preferably by review of archival tissue if available, fresh biopsy will not be required if inadequate tissue sample.\n* Age \\>= 6 years\n* ECOG performance status \\\u003C= 2 (Karnofsky or Lansky \\>= 60%)\n* Ability of participant or parent\u002Fguardian to understand and the willingness to sign a written informed consent document.\n\nEXCLUSION CRITERIA:\n\n\\- Non-modifiable medical comorbidities that would preclude cytoreductive surgery.","ALL","6 Years",{"count":19,"type":20},400,"ESTIMATED","OBSERVATIONAL","Objective:\n\nTo follow people with GISTs and collect tumor tissue so that it can be studied in the lab.\n\nEligibility:\n\nPeople age 6 and older who have a GIST.\n\nDesign:\n\nParticipants will be screened with a review of their medical records and samples.\n\nParticipants will enroll in 1 other NIH study, and may be asked to enroll in 2 other optional NIH studies.\n\nParticipants will have a medical history and physical exam. Data about how they function in their daily activities will be obtained.\n\nParticipants may speak with a genetic counselor. They may have genetic testing.\n\nParticipants will give blood samples. They may have a cheek swab. For this, small brush will be rubbed against the inside of the cheek.\n\nParticipants may have a computed tomography (CT) scan of the chest, abdomen, and pelvis. Or they may have a CT scan of the chest and magnetic resonance imaging (MRI) of the abdomen and pelvis.\n\nParticipants will be monitored every 6-12 months at the NIH Clinical Center, for up to 10 years before having surgery. If they need surgery, it will be performed at the NIH. Then, they will be monitored every 6-12 months, for up to 5 years after surgery.\n\nIf a participant has surgery, tumor tissue samples and research specimen will be taken.\n\nIf a participant does not need surgery, their participation will end after 10 years. If they have surgery, the 5-year monitoring period will restart after each surgery.",[24,25,26,27,28],"Gastric Cancer","Gastric Neoplasm","Gastrointestinal Stromal Sarcoma","Gastrointestinal Stromal Neoplasm","Gastrointestinal Stromal Tumor (GIST)",[30,31,32,33,34,35],"Tyrosine Kinase Inhibitor (TKI) Therapy","Wild-Type GISTs (WT GISTs)","PDGFRA Mutation","KIT Mutation","SDH Mutation","Natural History","RECRUITING","2026-06-23",{"date":39,"type":40},"2026-06-24","ACTUAL",{"date":42,"type":40},"2020-12-18",{"date":44,"type":20},"2040-12-30",{"name":46,"class":47},"National Cancer Institute (NCI)","NIH",1,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":4,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":16,"minAge":56,"maxAge":4,"enrollmentInfo":57,"targetDuration":4,"studyType":59,"phases":60,"briefSummary":62,"conditions":63,"keywords":65,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":48},"100554173","miss-rate-of-gastric-neoplasms-under-computer-aided-endoscopy-100554173","NCT06495645","Miss Rate of Gastric Neoplasms Under Computer-aided Endoscopy","Computer-aided Gastric Lesion Localization and Miss Rate of Gastric Neoplasms: a Tandem, Randomized Controlled Study","Inclusion Criteria:\n\n* Patients aged 40 or older\n* Scheduled for elective upper endoscopy\n\nExclusion Criteria:\n\n* Pregnant women,\n* Inability to provide written informed consent\n* Prior gastrectomy, and\n* Patients deemed unsuitable or high-risk for endoscopy with severe comorbid illnesses","40 Years",{"count":58,"type":20},1000,"INTERVENTIONAL",[61],"NA","This prospective randomized trial compares AI-assisted upper gastrointestinal endoscopy with high definition upper gastrointestinal endoscopy in term of missed rate of gastric neoplasm. The investigators hypothesize the miss rate of high definition upper gastrointestinal endoscopy is higher than AI-assisted upper gastrointestinal endoscopy.",[25,64],"Artificial Intelligence",[25,66,67],"Artificial intelligence","Miss rate","2025-11-19",{"date":70,"type":40},"2025-11-20",{"date":72,"type":40},"2024-11-01",{"date":74,"type":20},"2026-12-31",{"name":76,"class":77},"The University of Hong Kong","OTHER",{"id":79,"slug":80,"hasResults":11,"nctId":81,"briefTitle":82,"officialTitle":83,"acronym":4,"eligibilityCriteria":84,"healthyVolunteers":11,"sex":16,"minAge":85,"maxAge":86,"enrollmentInfo":87,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":89,"conditions":90,"keywords":96,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":102,"lastUpdatePostDateStruct":103,"startDateStruct":105,"completionDateStruct":107,"leadSponsor":109,"locationsCount":48},"100422394","endoscopic-resection-of-gastrointestinal-neoplasms-100422394","NCT04780256","Endoscopic Resection of Gastrointestinal Neoplasms","Retrospective Study of Efficacy and Safety of the Endoscopic Removal of Cancerous and Precancerous Lesions of the Upper and Lower Digestive Tract","Inclusion Criteria:\n\n* 18 years or older\n* all patients who have undergone endoscopic resection of an upper or lower digestive tract tumor\n\nExclusion Criteria:\n\n* age under 18\n* inability to provide informed consent","18 Years","100 Years",{"count":88,"type":20},2000,"The study aims to retrospectively investigate the endoscopic resection procedures of cancerous and precancerous lesions of the upper and lower digestive tract in order to evaluate the efficacy and safety outcomes and to compare different resection techniques. In particular, the resection techniques investigated will be mucosectomy, en bloc and piecemeal, endoscopic submucosal dissection (ESD) and its variants, full-thickness resection. The anatomical districts involved will be the esophagus, stomach, duodenum, colon and rectum.",[91,92,25,93,94,95],"Endoscopic Mucosal Resection","Endoscopic Submucosal Dissection","Colonic Neoplasms","Esophageal Neoplasms","Duodenal Neoplasms",[97,98,99,100,101],"Endoscopic mucosal resection (EMR)","Endoscopic submucosal dissection (ESD)","Endoscopic full thickness resection (EFTR)","Colorectal ESD","Colorectal EMR","2025-09-30",{"date":104,"type":40},"2025-10-03",{"date":106,"type":40},"2021-03-15",{"date":108,"type":20},"2025-12",{"name":110,"class":111},"Azienda USL Reggio Emilia - IRCCS","OTHER_GOV",{"id":113,"slug":114,"hasResults":11,"nctId":115,"briefTitle":116,"officialTitle":117,"acronym":4,"eligibilityCriteria":118,"healthyVolunteers":11,"sex":16,"minAge":85,"maxAge":4,"enrollmentInfo":119,"targetDuration":4,"studyType":59,"phases":121,"briefSummary":124,"conditions":125,"keywords":4,"overallStatus":126,"whyStopped":4,"lastUpdateSubmitDate":127,"lastUpdatePostDateStruct":128,"startDateStruct":130,"completionDateStruct":132,"leadSponsor":134,"locationsCount":4},"100591179","phase-2-efficacy-and-safety-of-fruquintinib-combined-with-sintilimab-and-stereotactic-body-radiation-therapy-sbrt-for-the-second-line-and-higher-line-treatment-of-gastric-or-gastroesophageal-junction-adenocarcinoma-with-oligometastatic-progression-100591179","NCT06977061","Efficacy and Safety of Fruquintinib Combined With Sintilimab and Stereotactic Body Radiation Therapy (SBRT) for the Second-line and Higher-line Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma With Oligometastatic Progression","A Single-Arm, Open-Label Phase II Clinical Study of Fruquintinib Combined With Sintilimab and Stereotactic Body Radiation Therapy (SBRT) for the Second-Line and Higher-Line Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma With Oligometastatic Progression","Inclusion Criteria:\n\n1. Have fully understood this study and voluntarily signed the informed consent form;\n2. Be at least 18 years old, regardless of gender;\n3. Have histologically and\u002For cytologically confirmed metastatic or locally advanced gastric or gastroesophageal junction adenocarcinoma, and have experienced at least one failure of systemic treatment (Note: The previously accepted systemic treatment regimens in this protocol include chemotherapy alone or in combination with multiple drugs, or immunotherapy combined with chemotherapy, or failure after receiving anti-HER-2 targeted therapy for HER-2 positive cases. Failure is defined as intolerable toxic side effects, disease progression during treatment, or recurrence after the end of treatment);\n4. Have an Eastern Cooperative Oncology Group (ECOG) performance status score of 0-1;\n5. Have an expected survival of ≥ 12 weeks;\n6. Have at least one measurable lesion (according to RECIST 1.1);\n7. Have normal major organ functions, meeting the following criteria:\n\n1.Blood routine examination: Hemoglobin (Hb) ≥ 90g\u002FL; Absolute neutrophil count (ANC) ≥ 1.5×10⁹\u002FL; Platelet count (PLT) ≥ 100×10⁹\u002FL; White blood cell count (WBC) ≥ 3.0×10⁹\u002FL; 2.Biochemical examination: Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5× the upper limit of normal (ULN) (for patients with liver metastasis, ≤ 5×ULN); Serum total bilirubin (TBIL) ≤ 1.5×ULN (for subjects with Gilbert's syndrome, ≤ 3×ULN; for patients with liver metastasis, total bilirubin ≤ 3×ULN); Serum creatinine (Cr) ≤ 1.5×ULN or creatinine clearance rate ≥ 50ml\u002Fmin; 3.Coagulation function: Activated partial thromboplastin time (APTT), international normalized ratio (INR), prothrombin time (PT) ≤ 1.5×ULN; 4.Doppler ultrasound assessment: Left ventricular ejection fraction (LVEF) ≥ 50%; 8.For subjects with potential fertility, they need to use at least one medically approved contraceptive measure (such as an intrauterine device, contraceptive pills, or condoms) during the study treatment period and within 180 days after the end of the study treatment; and the serum\u002Furine human chorionic gonadotropin (HCG) test must be negative before the first administration; and they must not be lactating.\n\nExclusion Criteria:\n\n1. Have previously received treatment with VEGF or VEGFR inhibitors;\n2. Have received live vaccines within 4 weeks before enrollment or are likely to receive them during the study period;\n3. Have had an autoimmune disease or a history of autoimmune disease within 4 weeks before enrollment;\n4. Have previously received allogeneic bone marrow transplantation or organ transplantation;\n5. Have had another malignant tumor within 5 years before enrollment, except for skin basal cell carcinoma or squamous cell carcinoma after radical resection, or cervical carcinoma in situ;\n6. Have symptomatic or active central nervous system (CNS) metastases or carcinomatous meningitis (patients with asymptomatic or stable brain metastases after treatment are allowed to be included);\n7. Have a history of severe cardiovascular and cerebrovascular diseases:\n\n   * Have experienced cerebrovascular accident (excluding lacunar infarction, mild cerebral ischemia or transient ischemic attack, etc.) within 6 months before the first administration of the study drug, myocardial infarction, unstable angina pectoris, uncontrolled arrhythmia (including QTc interval ≥ 450ms for men and ≥ 470 ms for women) (QTc interval is calculated using the Fridericia formula);\n   * Have a New York Heart Association (NYHA) cardiac function classification \\> grade II or a left ventricular ejection fraction (LVEF) \\\u003C 50%;\n8. Have clinically uncontrolled active infections, such as acute pneumonia, active hepatitis B or hepatitis C (for a history of hepatitis B virus infection, regardless of drug control, hepatitis B virus DNA ≥ 1×10⁴ copies\u002FmL or \\> 2000 IU\u002Fml);\n9. Have uncontrollable malignant ascites (defined as ascites that cannot be controlled by diuretics or puncture as judged by the researcher);\n10. Have uncontrolled hypertension that cannot be controlled by drugs currently, defined as systolic blood pressure ≥ 150 mmHg and\u002For diastolic blood pressure ≥ 100 mmHg (except for patients whose blood pressure can be controlled by dual-drug antihypertensive treatment before enrollment);\n11. Have urine routine indicating proteinuria ≥ 2+ and 24-hour urinary protein quantification \\> 1.0g;\n12. Have active ulcers in the stomach and duodenum, digestive tract diseases such as ulcerative colitis, or active bleeding in unresected tumors, or other conditions that may cause gastrointestinal bleeding or perforation as determined by the researcher;\n13. Have active bleeding or a bleeding tendency;\n14. Have diseases or conditions that affect the absorption of the drug currently, or be unable to take fruquintinib orally;\n15. Have experienced allergic reactions to fruquintinib and\u002For the excipients in the test drug;\n16. Be considered by the researcher as unsuitable for enrollment in this study.",{"count":120,"type":20},30,[122,123],"PHASE2","PHASE3","Efficacy and safety of fruquintinib in combination with sintilizumab and SBRT in the treatment of oligonadenocarcinoma progression in the stomach or gastroesophageal junction",[25],"NOT_YET_RECRUITING","2025-05-10",{"date":129,"type":40},"2025-05-16",{"date":131,"type":20},"2025-06-01",{"date":133,"type":20},"2026-09-01",{"name":135,"class":77},"Queling Liu",{"id":137,"slug":138,"hasResults":11,"nctId":139,"briefTitle":140,"officialTitle":141,"acronym":142,"eligibilityCriteria":143,"healthyVolunteers":11,"sex":16,"minAge":85,"maxAge":144,"enrollmentInfo":145,"targetDuration":4,"studyType":59,"phases":147,"briefSummary":148,"conditions":149,"keywords":164,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":173,"lastUpdatePostDateStruct":174,"startDateStruct":176,"completionDateStruct":178,"leadSponsor":180,"locationsCount":182},"100518299","phase-2-total-neoadjuvant-flot-chemotherapy-in-locally-advanced-gastric-and-gastroesophageal-junction-cancer-100518299","NCT06028737","Total Neoadjuvant FLOT Chemotherapy in Locally Advanced Gastric and Gastroesophageal Junction Cancer","Total Neoadjuvant Chemotherapy With 5-fluoruracil, Leucovorin, Oxaliplatin, and Docetaxel in Locally Advanced Gastric and Gastroesophageal Junction Cancer (OCTASUR): Randomized, Multi-center, Open-label Trial, Phase 2\u002F3","OCTASUR","Inclusion Criteria:\n\n* Tumor spread according to TNM: ≥cT3 and\u002For ≥cN0 and M0 (except of invasion of the common hepatic artery, celiac trunk, proximal part of the splenic artery, aorta, head of the pancreas);\n* Performance status by Eastern Cooperative Oncology Group (ECOG): 0 - 1;\n* Histologically confirmed gastric adenocarcinoma or gastroesophageal junction (Siewert type 2\u002F3) adenocarcinoma.\n* Differentiation grade: G0 - G4;\n* Tumor localization: cardio-esophageal junction (Siewert 2, 3), cardiac part of the stomach, body of the stomach, antral part of the stomach, pyloric part of the stomach;\n* Tumor extension: esophagus, diaphragm, liver, body and tail of the pancreas, anterior abdominal wall, small and large intestine, distal part of the splenic artery, spleen;\n* Patient agrees to participate in this biomedical study.\n\nExclusion Criteria:\n\n* Presence of another oncological disease at a different site if less than 5 years have passed since radical treatment.\n* Comorbidities or patient conditions that preclude the administration of chemotherapy.","80 Years",{"count":146,"type":20},150,[122,123],"The main goal of this study is to investigate the proportion of participants with locally advanced gastric and gastroesophageal adenocarcinoma without previous treatment during the last 5 years who can tolerate all planned cycles of chemotherapy and radical surgical treatment who will be prospectively randomized into two groups to undergo one of two chemotherapy regimens, followed by surgery:\n\n1. 8 cycles of Total Neoadjuvant ChemoTherapy (TNT) with 5-Fluorouracil (5-FU), Leucovorin, Oxaliplatin, and Docetaxel (FLOT) followed by surgery.\n2. 4 cycles of Neoadjuvant FLOT chemotherapy scheme preoperatively and 4 adjuvant FLOT cycles postoperatively.",[24,150,151,152,153,154,25,155,156,157,158,159,160,161,162,163],"Stomach Cancer","GastroEsophageal Cancer","Gastric Adenocarcinoma","Gastroesophageal Junction Adenocarcinoma","Advanced Gastric Adenocarcinoma","Stomach Neoplasm","Gastrointestinal Cancer","Advanced Gastroesophageal Junction Adenocarcinoma","Advanced Gastric Carcinoma","Chemotherapy","Gastrectomy","Gastrectomy for Gastric Cancer","Gastric Resection","Gastric (Cardia, Body) Cancer",[165,166,167,160,168,169,170,171,172],"Total neoadjuvant chemotherapy","FLOT","Fluoruracil","Perioperative chemotherapy","Docetaxel","Leucovorin","Gastric resection","Gastric cancer","2025-04-30",{"date":175,"type":40},"2025-05-06",{"date":177,"type":40},"2025-03-25",{"date":179,"type":20},"2032-12-31",{"name":181,"class":77},"Ukrainian Society of Clinical Oncology",2,{"id":184,"slug":185,"hasResults":11,"nctId":186,"briefTitle":187,"officialTitle":187,"acronym":188,"eligibilityCriteria":189,"healthyVolunteers":11,"sex":16,"minAge":85,"maxAge":4,"enrollmentInfo":190,"targetDuration":192,"studyType":21,"phases":4,"briefSummary":193,"conditions":194,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":177,"lastUpdatePostDateStruct":200,"startDateStruct":202,"completionDateStruct":204,"leadSponsor":206,"locationsCount":48},"100501059","the-australia-and-new-zealand-multicentre-upper-gastrointestinal-endoscopic-tissue-resection-study-100501059","NCT05804331","The Australia and New Zealand Multicentre Upper Gastrointestinal Endoscopic Tissue Resection Study","ANZ UGI","Inclusion Criteria:\n\n* UGI neoplastic lesions \\> 10mm\n\n  * Lesions for ESD limited to the mucosal and\u002For submucosal layer OR\n  * Lesions for EFTR limited to the muscularis propria layer OR\n  * Lesions for STER limited to the submucosal and\u002For muscularis propria layer\n* Aged 18 years or older\n\nExclusion Criteria:\n\n* Age less than 18\n* Unable to give informed consent\n* Pregnant or lactating patients\n* Patients with bleeding diathesis or who cannot discontinue ADP blockers (e.g. clopidogrel, prasugrel) or antithrombotics (e.g. warfarin, dabigatran) periprocedurally",{"count":191,"type":20},500,"3 Years","To determine the long term outcomes of Endoscopic Submucosal Dissection (ESD), Endoscopic Full Thickness Resection (EFTR) and Submucosal-Tunnelling Endoscopic Resection (STER) for upper gastrointestinal neoplastic lesions",[195,196,24,152,197,198,199,25,94],"Cancer of Stomach","Oesophageal Cancer","GI Cancer","GIST","Neuroendocrine Tumors",{"date":201,"type":40},"2025-03-27",{"date":203,"type":40},"2023-03-14",{"date":205,"type":20},"2028-09-14",{"name":207,"class":77},"Western Sydney Local Health District",{"id":209,"slug":210,"hasResults":11,"nctId":211,"briefTitle":212,"officialTitle":213,"acronym":4,"eligibilityCriteria":214,"healthyVolunteers":11,"sex":16,"minAge":85,"maxAge":4,"enrollmentInfo":215,"targetDuration":192,"studyType":21,"phases":4,"briefSummary":217,"conditions":218,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":222,"lastUpdatePostDateStruct":223,"startDateStruct":225,"completionDateStruct":227,"leadSponsor":229,"locationsCount":48},"100570087","the-correlation-between-blood-concentration-of-sintilimab-and-efficacy-and-adverse-reactions-in-patients-with-advanced-gastric-cancer-100570087","NCT06702683","The Correlation Between Blood Concentration of Sintilimab and Efficacy and Adverse Reactions in Patients with Advanced Gastric Cancer","Study on the Correlation Between Blood Concentration of Sintilimab and Related Predictors with Efficacy and Adverse Reactions in Patients with Advanced Gastric Cancer","Inclusion Criteria:\n\nA. Patients who were diagnosed with gastric adenocarcinoma or gastroesophageal junction adenocarcinoma; B. Patients who plan to be treated with Sintilimab; C.ECOG score of 0-2; D. Expected survival ≥3 months; E. The patient who have good compliance, follow-up, and can cooperate with relevant treatment and examination; F. Agree to participate in the study and sign the informed consent\n\nExclusion Criteria:\n\nA. Patients who clinical information and data are incomplete; B. Patients who treated with immune checkpoint inhibitors within 6 months",{"count":216,"type":20},112,"Compared with other anti-tumor drugs, immune checkpoint inhibitors (ICIs) have their own unique pharmacokinetics (PK) and pharmacodynamics (PD), and affect patient clinical outcomes. However, at present, the data on the PK and PD characteristics of ICIs in the Chinese population are still lacking, thus further clinical trials are needed to verify them. At the same time, a large proportion of patients have no response to ICIs or the efficacy is poor, and even bring greater side effects, so it is particularly important to find effective biomarkers to predict the efficacy and adverse reactions of patients with ICIs treatment.The purpose of this study is to explore the correlation between blood concentration of Sintilimab and related predictors with efficacy and adverse reactions in patients with advanced gastric cancer so as to provide clinical reference for individualized treatment of patients with gastric cancer.",[219,25,220,221],"Gastric Carcinoma","Gastric (cardia, Body) Cancer","Gastric Cancer Adenocarcinoma Metastatic","2024-11-21",{"date":224,"type":40},"2024-11-25",{"date":226,"type":40},"2023-02-17",{"date":228,"type":20},"2025-12-31",{"name":230,"class":77},"Lin Liu"]